期刊文献+

原发性骨淋巴瘤23例

原文传递
导出
摘要 目的探讨原发性骨淋巴瘤(PBL)的治疗及预后。方法对经病理证实的23例PBL患者资料进行回顾性分析。结果23例患者中,弥漫大B细胞性淋巴瘤18例,淋巴浆细胞样淋巴瘤1例,套细胞淋巴瘤1例,外周T细胞性淋巴瘤2例,间变大细胞性淋巴瘤1例,I Ea期9例,I Eb期2例,Ⅱ Ea期6例,Ⅱ Eb期3例,Ⅲ Ea期1例,Ⅲ Eb期2例。治疗总体反应率91.3%(21/23),完全缓解(CR)率为65.2%(15/23)。3年总体生存率为783%(18/23),5年生存率为56.5%(13/23)。结论PBL临床表现无明显特异性,早期诊断、综合治疗有潜在治愈的可能。IPI评分有可能是其预后的重要指标之一。
出处 《白血病.淋巴瘤》 CAS 2011年第10期620-621,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献6

  • 1Xia,Y.-N.;Gates,B.;Yin,Y.-D.;Lu,Y.Adv.Mater.2000,10,693.
  • 2Charlton,M.D.B.;Zoorob,M.E.;Parker,G.J.;Netti,M.C.;Baumberg,J.J.;Cox,S.J.;Kemhadjian,H.Mater.SCi.Eng.,B 2000,B74,17.
  • 3程淑琴,谢伟成,谢碧霞,陈成坚,曹小龙.美罗华联合化疗治疗B细胞非霍奇金淋巴瘤的临床分析[J].临床血液学杂志,2008,21(2):157-159. 被引量:6
  • 4Jiang,P.;Bertone,J.F.;Hwang,K.S.;Colvin,V.L.Chem.Mater.1999,11,2132.
  • 5Velev,O.D.;Kaler,E.W.Adv.Mater.2000,7,531.
  • 6Biswas,R.;Sigalas,M.M.;Subramania,G.;Soukoulis,C.M.;Ho,K.-M.Phys.Rev.B: Condens.Matter Mater.Phys.2000,61,4549.

二级参考文献9

  • 1林桐榆,张红雨,黄岩,管忠震,沈悌,石远凯,朱军,克晓燕,王华庆,沈志祥,于世英,刘霆,施笑利.R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症,2005,24(12):1421-1426. 被引量:47
  • 2JAMES JS,DUBS G. FDA approves new kind of lymphoma treatment. Food and Drug Administration[J]. AIDS Treat News, 1997,5:2--3.
  • 3GRILI.O I.OPE;Z A J, CHESON B D, HOMING S J, et al. Response critqria for NHL :important of nomal lymph node size and correlations with response rates [J]. Ann Oncol,2000,11:399--408.
  • 4DAVIS T A, GRILLO LOPEZ A J,WlTE C A, et al. Rituximab anti CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to 'a four dose treatment program[J ]. J Clin Oncol, 1998,16 : 2825 - 2828.
  • 5MCLAUGHLIN P, WHITE C A, LINK B K,et al. Rituximab chimeric anti-CD20 monocloal antibody therapy for relapsed indolent lymphoma: half of patients respond to a fourdoes treatment program[J]. J Chin Oncol,1998,16;2825 -2829.
  • 6DERVITE I, HOBER D,MOREL P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab[J]. N Engl J Med, 2001,344:68--69.
  • 7NG H J, LIM LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabin and rituximab therapy: case report [J]. Ann Hematol, 2001,80:549--522.
  • 8KAMI M, HAMAKI T, MURASHIGE N, et al Safety of rituximab in lymphoma patients with hepat tis B or hepatitis C virus infection [J]. Hematol J 2003,4:159--162.
  • 9MINGSHEN D, TSUYI C, WOEIYAU K. et al. De layed hepatitis B virus reactivation after cessation of prermptive lamivudine in lymphoma patients treated with rituximab plus CHOP [J]. Ann Hematol ,2004: 769--774.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部